[The Nanjing Intermediate Court handed down a preliminary judgment in the first instance judgment in accordance with the law on the lawsuit of the Special Representative of Jin Tongling Securities.] The head of the relevant department of the Securities Regulatory Commission answered questions from reporters. The reporter asked: Recently, the Nanjing Intermediate Court handed down a preliminary judgment in the first instance judgment in accordance with the law in the lawsuit against the representative of Jin Tongling Securities's misrepresentation. As a regulator, how do you view this lawsuit? The Securities Regulatory Commission answered: Following the Kangmei Pharmaceutical case and the Zeda Yisheng case, the Jin Tongling case is another securities misrepresentation liability dispute where the special representative's litigation procedure was applied to arrive at the outcome of a physical trial. The case in question effectively exploited the special representative's litigation system function of “express withdrawal and implied participation”, representing investors at low cost in an intensive way to protect their rights and interests and resolve conflicting disputes. It also made the special representative litigation system an important legal method for collaborative management of securities administration supervision and judicial adjudication, and strongly deterring potential violations of laws and regulations in the securities market.

[The Nanjing Intermediate Court handed down a preliminary judgment in the first instance judgment in accordance with the law on the lawsuit of the Special Representative of Jin Tongling Securities.] The head of the relevant department of the Securities Regulatory Commission answered questions from reporters. The reporter asked: Recently, the Nanjing Intermediate Court handed down a preliminary judgment in the first instance judgment in accordance with the law in the lawsuit against the representative of Jin Tongling Securities's misrepresentation. As a regulator, how do you view this lawsuit? The Securities Regulatory Commission answered: Following the Kangmei Pharmaceutical case and the Zeda Yisheng case, the Jin Tongling case is another securities misrepresentation liability dispute where the special representative's litigation procedure was applied to arrive at the outcome of a physical trial. The case in question effectively exploited the special representative's litigation system function of “express withdrawal and implied participation”, representing investors at low cost in an intensive way to protect their rights and interests and resolve conflicting disputes. It also made the special representative litigation system an important legal method for collaborative management of securities administration supervision and judicial adjudication, and strongly deterring potential violations of laws and regulations in the securities market.